Opportunity Information: Apply for PAR 18 866
The grant opportunity titled "Pre-Application: Research Innovation for Scientific Knowledge (RISK) for Skin and Rheumatic Diseases (X02 Clinical Trial Not Allowed)" is an NIH (NIAMS) funding announcement designed to surface bold, unconventional ideas in skin and rheumatic disease research that often struggle to compete in traditional NIH mechanisms. The central theme is high-risk, high-reward science that challenges prevailing assumptions or standard practice. NIAMS is explicitly looking for proposals built around unusual observations, imaginative hypotheses, creative concepts, or new paradigms that could reshape understanding in areas within the NIAMS mission, even if the ideas seem premature, controversial, or not yet fully supported by extensive preliminary data. The intent is to encourage investigators to take scientific chances where the payoff could be substantial, rather than rewarding only incremental advances.
The scientific scope is disease-focused and translational, meaning applicants are expected to connect their work to specific skin or rheumatic diseases or conditions relevant to NIAMS. The announcement invites studies that dig into underlying mechanisms of disease, including biological pathways and processes that drive onset, progression, or severity. In addition, it welcomes projects aimed at developing or testing diagnostics, therapeutic agents, or preventive interventions, with an important boundary: work may progress up to, but not including, first-in-human studies. This places the emphasis on preclinical and translational research stages such as target validation, proof-of-concept experiments, biomarker development, assay development, prototype diagnostic testing, and preclinical evaluation of candidate therapeutics or prevention strategies. At the same time, the announcement clearly states that the RISK R61/R33 program is not intended to support clinical trials, and the specific listing here is marked "Clinical Trial Not Allowed," reinforcing that human interventional clinical trial activity is outside the allowed scope.
Administratively, this is a discretionary grant opportunity from the National Institutes of Health under CFDA 93.846, categorized under health-related funding activities. The opportunity number is PAR 18 866, and it is presented as a pre-application mechanism (X02). The posted original closing date was 2018-08-10, and the record does not list an award ceiling or expected number of awards in the provided data. Because it is a pre-application, the general expectation is that applicants submit an initial concept or preliminary package for consideration before being invited or guided toward a subsequent full application stage, helping NIAMS identify the most compelling high-risk ideas early and reducing the burden of preparing a full application that may not be aligned with program goals.
Eligibility is broad across U.S.-based organizations and governmental entities. Eligible applicants include state, county, city or township governments, special district governments, independent school districts, and federally recognized tribal governments. Higher education institutions are eligible, including public/state-controlled and private institutions of higher education. A wide range of nonprofit entities may apply, both those with and without 501(c)(3) IRS status (when not applying as institutions of higher education). For-profit organizations (other than small businesses) and small businesses are also listed as eligible, along with certain other categories such as public housing authorities/Indian housing authorities and tribal organizations that are not federally recognized tribal governments. The announcement also highlights inclusion of mission-relevant institution types and community-linked organizations, including Alaska Native and Native Hawaiian Serving Institutions, AANAPISISs, Hispanic-serving institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, eligible federal agencies, regional organizations, and U.S. territories or possessions.
Foreign participation is restricted in a straightforward way: non-domestic (non-U.S.) entities and non-domestic components of U.S. organizations are not eligible to apply, and foreign components as defined in the NIH Grants Policy Statement are not allowed. In practical terms, that means the applicant organization must be U.S.-based and the proposed work cannot include a foreign component as NIH defines it, which limits the ability to place substantive project elements or performance sites outside the United States under this funding opportunity.
Overall, this opportunity is best suited for teams proposing ambitious, mechanism-driven or translationally oriented research in skin and rheumatic diseases where the core idea is genuinely novel and carries real uncertainty, but is still anchored to a clear disease relevance and a credible path toward generating decisive evidence. It is not meant for clinical trial execution, and it is not meant for conventional, incremental projects; it is meant for researchers prepared to test a daring idea with the potential to open new directions for diagnosis, prevention, or treatment prior to any first-in-human step.Apply for PAR 18 866
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Pre-Application: Research Innovation for Scientific Knowledge (RISK) for Skin and Rheumatic Diseases (X02 Clinical Trial Not Allowed)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.846.
- This funding opportunity was created on 2018-07-23.
- Applicants must submit their applications by 2018-08-10. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs)
What is the title of this grant opportunity?
The opportunity is titled "Pre-Application: Research Innovation for Scientific Knowledge (RISK) for Skin and Rheumatic Diseases (X02 Clinical Trial Not Allowed)."
Which agency is offering this opportunity?
This is a National Institutes of Health (NIH) funding opportunity from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS).
What is the funding opportunity number?
The opportunity number provided is PAR 18 866.
What does "X02" mean in this announcement?
The listing is presented as a pre-application mechanism (X02). Based on the information provided, this indicates an initial submission stage where an early concept or preliminary package is submitted for consideration before an applicant is invited or guided toward a subsequent full application stage.
What is the main goal of the RISK program described here?
The program is designed to surface bold, unconventional ideas in skin and rheumatic disease research that often struggle to compete in traditional NIH mechanisms. The emphasis is on high-risk, high-reward science that challenges prevailing assumptions or standard practice, with the potential to reshape understanding within the NIAMS mission.
What kinds of ideas is NIAMS explicitly looking for?
NIAMS is seeking proposals built around unusual observations, imaginative hypotheses, creative concepts, or new paradigms. The opportunity is intended to encourage ideas that may seem premature, controversial, or not yet supported by extensive preliminary data, as long as they are compelling and could lead to substantial scientific payoff.
Is this opportunity intended for incremental or conventional research projects?
No. The description emphasizes that it is not meant to reward only incremental advances. It is aimed at investigators prepared to take scientific chances where the payoff could be substantial.
What is the scientific scope of the research?
The scope is disease-focused and translational, meaning applicants are expected to connect the proposed work to specific skin or rheumatic diseases or conditions relevant to the NIAMS mission.
Are mechanistic studies within scope?
Yes. The announcement invites studies that dig into underlying mechanisms of disease, including biological pathways and processes that drive onset, progression, or severity.
Are diagnostics, therapeutics, or prevention projects allowed?
Yes. The opportunity welcomes projects aimed at developing or testing diagnostics, therapeutic agents, or preventive interventions, within the boundaries described in the announcement.
How far can translational work go under this opportunity?
Work may progress up to, but not including, first-in-human studies. The emphasis is on preclinical and translational stages such as target validation, proof-of-concept experiments, biomarker development, assay development, prototype diagnostic testing, and preclinical evaluation of candidate therapeutics or prevention strategies.
Are clinical trials allowed under this funding opportunity?
No. The announcement clearly states that the RISK R61/R33 program is not intended to support clinical trials, and this specific listing is marked "Clinical Trial Not Allowed." Human interventional clinical trial activity is outside the allowed scope based on the information provided.
Does "Clinical Trial Not Allowed" also rule out first-in-human studies?
Yes. The provided description draws a firm boundary that work may progress up to, but not including, first-in-human studies, and also reiterates that clinical trials are not supported under this opportunity.
What type of funding opportunity is this described as?
It is described as a discretionary grant opportunity from the National Institutes of Health under CFDA 93.846, categorized under health-related funding activities.
What is the CFDA number associated with this opportunity?
The CFDA number provided is 93.846.
What was the original closing date listed for this opportunity?
The posted original closing date was 2018-08-10.
Is an award ceiling or the expected number of awards provided?
No. The provided record does not list an award ceiling or an expected number of awards.
Why does NIAMS use a pre-application approach for this opportunity?
Based on the information provided, the pre-application approach helps NIAMS identify the most compelling high-risk ideas early and reduces the burden of preparing a full application that may not align with program goals.
Who is eligible to apply?
Eligibility is broad across U.S.-based organizations and governmental entities. Eligible applicants include various levels of U.S. government (state, county, city/township), special district governments, independent school districts, and federally recognized tribal governments. Higher education institutions (public/state-controlled and private) are eligible. A wide range of nonprofit entities may apply (with or without 501(c)(3) status, when not applying as institutions of higher education). For-profit organizations (other than small businesses) and small businesses are also listed as eligible. Additional eligible categories include public housing authorities/Indian housing authorities and tribal organizations that are not federally recognized tribal governments.
Are institutions such as HBCUs, HSIs, and Tribal Colleges included in eligibility?
Yes. The announcement highlights inclusion of mission-relevant institution types and community-linked organizations, including Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and AANAPISISs.
Are faith-based or community-based organizations eligible?
Yes. Faith-based or community-based organizations are explicitly listed among eligible categories.
Are U.S. territories or possessions included?
Yes. U.S. territories or possessions are listed among eligible applicant categories.
Are federal agencies eligible to apply?
Yes. Eligible federal agencies are included among the listed eligible applicants.
Can a non-U.S. (foreign) organization apply?
No. Non-domestic (non-U.S.) entities are not eligible to apply under this opportunity.
Can a non-U.S. component of a U.S. organization be included?
No. Non-domestic components of U.S. organizations are not eligible, and foreign components (as defined in the NIH Grants Policy Statement) are not allowed. In practical terms, the applicant must be U.S.-based and the proposed work cannot include a foreign component as NIH defines it.
What type of research team is this opportunity best suited for?
It is best suited for teams proposing ambitious, mechanism-driven or translationally oriented research in skin and rheumatic diseases where the core idea is genuinely novel and carries real uncertainty, but remains anchored to clear disease relevance and a credible path toward generating decisive evidence.
What is the central theme in how applications are expected to differ from typical NIH submissions?
The central theme is high-risk, high-reward science that challenges prevailing assumptions or standard practice. The opportunity is meant to elevate daring concepts that could open new directions for diagnosis, prevention, or treatment prior to any first-in-human step.
Browse more opportunities from the same category: Health
Next opportunity: Strategies to Provide Culturally Tailored Palliative and End-of-Life Care for Seriously Ill American Indian and Alaska Native Individuals (R01 Clinical Trial Optional)
Previous opportunity: Administrative Supplements for Research on Dietary Supplements (Admin. Supp.- Clinical Trial Not Allowed)
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 18 866
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 18 866) also looked into and applied for these:
| Funding Opportunity |
|---|
| Genome Sequencing Center for the Gabriella Miller Kids First Pediatric Research Program (U24 Clinical Trial Not Allowed) Apply for RFA RM 18 030 Funding Number: RFA RM 18 030 Agency: National Institutes of Health Category: Health Funding Amount: $8,000,000 |
| Novel Approaches for Relating Genetic Variation to Function and Disease (R21 Clinical Trial Not Allowed) Apply for PA 18 867 Funding Number: PA 18 867 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Novel Approaches for Relating Genetic Variation to Function and Disease (R01 Clinical Trial Not Allowed) Apply for PA 18 868 Funding Number: PA 18 868 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Research Innovations for Scientific Knowledge (RISK) for Skin and Rheumatic Diseases (R61/R33 Clinical Trial Not Allowed) Apply for RFA AR 19 012 Funding Number: RFA AR 19 012 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| Research to Advance Vaccine Safety (R01 Clinical Trial Not Allowed) Apply for PA 18 873 Funding Number: PA 18 873 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| HIV Drug Resistance: Genotype-Phenotype-Outcome Correlations (R01 Clinical Trial Not Allowed) Apply for RFA AI 18 029 Funding Number: RFA AI 18 029 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| Research to Advance Vaccine Safety (R21 Clinical Trial Not Allowed) Apply for PA 18 872 Funding Number: PA 18 872 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Biologic Factors Underlying Dental, Oral, and Craniofacial Health Disparities (R21 - Clinical Trial Not Allowed) Apply for PA 18 874 Funding Number: PA 18 874 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Innovative Technologies to Deliver Genome Editing Machinery to Disease-relevant Cells and Tissues (UG3/UH3 Clinical Trial Not Allowed) Apply for RFA RM 18 023 Funding Number: RFA RM 18 023 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| Biologic Factors Underlying Dental, Oral, and Craniofacial Health Disparities (R01 - Clinical Trial Not Allowed) Apply for PAR 18 875 Funding Number: PAR 18 875 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Innovative Technologies to Non-Invasively Monitor Genome Edited Cells In Vivo (UH2/UH3 Clinical Trial Not Allowed) Apply for RFA RM 18 025 Funding Number: RFA RM 18 025 Agency: National Institutes of Health Category: Health Funding Amount: $150,000 |
| Center for ELSI Resources and Analysis (U24 Clinical Trial Not Allowed) Apply for RFA HG 18 008 Funding Number: RFA HG 18 008 Agency: National Institutes of Health Category: Health Funding Amount: $1,000,000 |
| Late Stage Clinical Trials for the Spectrum of Alzheimers Disease and Age-related Cognitive Decline (R01 Clinical Trial Required) Apply for PAR 18 878 Funding Number: PAR 18 878 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Expanding Extramural Research Opportunities at the NIH Clinical Center (U01 Clinical Trial Optional) Apply for PAR 18 879 Funding Number: PAR 18 879 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Molecular Atlas of Lung Development Program (LungMAP) Phase 2 - Data Coordinating Center (U24- Clinical Trial Not Allowed) Apply for RFA HL 19 022 Funding Number: RFA HL 19 022 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Early Psychosis Intervention Network (EPINET): Data Coordinating Center (U24 Clinical Trial Not Allowed) Apply for RFA MH 19 151 Funding Number: RFA MH 19 151 Agency: National Institutes of Health Category: Health Funding Amount: $1,000,000 |
| Early Psychosis Intervention Network (EPINET): Practice-Based Research to Improve Treatment Outcomes (R01 Clinical Trial Optional) Apply for RFA MH 19 150 Funding Number: RFA MH 19 150 Agency: National Institutes of Health Category: Health Funding Amount: $1,000,000 |
| Genomic Innovator Award (R35 Clinical Trial Optional) Apply for RFA HG 18 006 Funding Number: RFA HG 18 006 Agency: National Institutes of Health Category: Health Funding Amount: $300,000 |
| HIV Services and Systems Strengthening (HS3) Apply for 72051718RFA00003 Funding Number: 72051718RFA00003 Agency: Dominican Republic USAID-Santo Domingo Category: Health Funding Amount: $19,500,000 |
| Technologies for Improving Minority Health and Eliminating Health Disparities (R41/R42- Clinical Trial Optional) Apply for RFA MD 18 010 Funding Number: RFA MD 18 010 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 18 866", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.